Organic Active Ingredients TRIZ Cases

Guaijaverin protects retinal cells from blue-light optical damage by reducing oxidative stress, inflammation, and apoptosis.

A modified-release oral minoxidil formulation smooths PK peaks to support hair regrowth while lowering adverse effects from immediate release.

Timed-release levodopa mini-tablets delay dosing until the small intestine, improving absorption predictability and morning akinesia control.

Henna-derived compounds inhibit Malassezia growth while helping address dandruff and scalp conditions with less disruption to scalp microbiome balance.

A modular RNA sensor targets Gfral-expressing area postrema neurons to modulate IL-6 signaling for cachexia and obesity therapy.

Selective biased KOR agonists reduce CNS penetration to relieve pain and hyperalgesia without sedation or neuromuscular incoordination.

Targeted siRNA or ASO inhibition of MS4A4E lowers liver fat, fibrosis, and NAFLD activity while improving metabolic markers.

Oxalic acid cocrystal forms improve stability and solubility of this kinase inhibitor while easing solid-form selection for drug development.

A poloxamer and elastin-collagen hydrogel stays injectable at room temperature, gels at body temperature, and releases drugs for up to 7 days.

Structural changes to camptothecin ADC payloads improve tumor-cell inhibition, plasma stability, targeting, and safety.

Folic acid-modified liposome-coated tilianin nanocrystals improve solubility, mucus penetration, and oral bioavailability for atherosclerosis therapy.

Using HPMC-AS solid dispersions, rifaximin delays refractory ascites and reduces hospitalization time in cirrhosis complications.

Hydrolyzable lipidoid LNPs improve liver nucleic acid delivery, endosomal escape, and tolerated dosing while reducing toxicity.

Selective bicyclic NNMT inhibitors target cancer-associated fibroblasts to reduce tumor burden while minimizing toxicity to normal tissues.

A six-amino-acid formulation speeds fluid absorption and supports tight junction integrity when gastric emptying and intestinal uptake limit hydration.

XRPD and thermal analysis distinguish Cot inhibitor solid forms, enabling reliable selection and quality control for therapeutic use.

Hydrophilic rosmarinic acid derivatives self-assemble into microparticles that improve solubility, bioavailability, and anti-inflammatory delivery.

Single-stranded oligonucleotides degrade MLH3 mRNA to curb trinucleotide repeat expansion and slow related neurodegenerative disorders.

A pyrazolopyrimidine scaffold with tailored 3- and 5-substituents expands Trk kinase inhibition across cancers and related diseases.

Sequential two-step mixing separates core nucleation from stabilization to achieve up to 95% nanoparticle loading with stable sub-100 nm particles.

An abluminal-only antiproliferative coating separates drug delivery from degradation control to lower thrombosis and restenosis risk.

A polysiloxane or polyisobutylene patch matrix enables once-daily asenapine delivery with improved bioavailability and low skin irritation.

A cotinine-linked CAR T platform enables retargeting across antigens and selective CAR T cell removal to curb immunotoxicity.

Multiple steaming and maturation enrich black ginseng extract with Rk1 and Rg5 to inhibit influenza while reducing resistance and side effects.

Chiral backbone and sugar modifications improve oligonucleotide stability, uptake, and splicing activity while reducing toxicity and complement activation.

Selective P2X3 antagonists reduce afferent neuron sensitivity to relieve endometriosis pain with fewer side effects and less recurrence.

A spherical eye-contact support and guided needle angles improve ciliary muscle electroporation while reducing injury risk.

A Formula I inhibitor boosts USP28/USP25 inhibition while limiting structural complexity, helping destabilize c-MYC and LSD1 in tumors.

Novel Formula I compounds tune heteroaromatic substituents to inhibit SSAO and support treatment of inflammation, fibrosis, diabetes, stroke, and cancer.

Direct lung delivery of inhaled ivermectin achieves therapeutic pulmonary concentrations while avoiding the safety limits of higher oral dosing.

Small molecule pyrazinotriazines inhibit CBP/β-catenin signaling to address inadequate Wnt pathway therapies for cancer, fibrosis, and diabetes.

Novel SSTR4 agonist salts improve excipient stability plus flow and bulk properties, supporting reliable pharmaceutical manufacturing and pain treatment.

A defined inulin DP profile lowers sinusitis risk, improves immune performance, and stays well tolerated over 6 months.

IV brincidofovir formulations use lyophilized or aqueous compositions to maintain antiviral exposure while reducing intestinal toxicity.

PEG-ended carbonate apatite particles improve lesion accumulation while reducing liver and other normal organ uptake for safer drug delivery.

Specific JAK inhibitor crystal forms improve solubility and thermal stability while enabling selective JAK1/TYK2 inhibition with better safety.

Nonapoptotic Formula A compounds trigger methuosis or autophagy to kill apoptosis-resistant cancer cells and improve drug sensitivity.

Small molecule receptor modulators improve glucose metabolism and weight control while avoiding the administration complexity of peptide therapies.

Glycomimetic fucose analogs selectively block FTVI and FTVII to suppress sLex formation while preserving Lewis X production.

Negatively charged polysaccharides are blended with RG-I pectin before heat-drying to limit aggregation and improve solubility.

Combining a CDK4/6 inhibitor with a KRAS G12C inhibitor helps overcome intrinsic resistance and improve potency across lung cancer cell lines.

Freezing CO2-rich amine solutions creates carbonic acid adducts with improved storage stability, enabling advance pharmaceutical preparation.

Selective 3CL protease inhibitors block SARS-CoV-2 replication while enabling oral, inhalation, and intranasal COVID-19 treatment.

Novel GPX4-targeting senolytic compounds improve solubility and oral bioavailability while selectively clearing senescent cells.

SBEβCD inclusion complexing with bicarbonate improves meloxicam solubility and bioavailability for faster oral absorption and pain relief.

Selective CBP/EP300 bromodomain inhibitors improve therapeutic efficacy while limiting off-target effects by modulating acetylation-driven transcription.

An in vitro pDC activation assay identifies gastric-tolerant lactic acid bacteria that induce interferon for antiviral prophylaxis.

Structural changes in 2-aminopyrimidine TLR8 modulators improve activity, selectivity, safety, and pharmacokinetics for immune-related diseases.

Combining targeted B-cell therapy with IL-6 modulation and optional CXCR4 inhibition helps lower IgM, reduce resistance, and improve apoptosis.

Crystallizing eribulin salts through diacid and low molecular weight amine complexation improves purity, stability, and moisture resistance.

Lactobacillus plantarum HAC03 hydrolyzes rutin into quercetin in the gut, improving bioavailability for obesity and insulin resistance treatment.

Low and variable eradication in non-immunogenic tumors is addressed by raising metabolic activity before BA-PDT and actinic-light exposure.

Platinum drugs can limit tumor treatment through nephrotoxicity; this derivative enhances antitumor activity while mitigating kidney damage.

R1–R6 substituent changes yield thiazolylphenol compounds targeting resistant and persister strains while remaining non-toxic in human cell lines.

Afucosylation removes Fc fucose at Asn297 to improve ADCC and Fc gamma RIIIA affinity while retaining FGFR2IIIb selectivity.

Prebiotics administered before, during, and after probiotic treatment support colonization stability and persistence while addressing dysbiosis.

Cellulose or amino acid excipients help preserve rilpivirine particle size and hyaluronidase function during refrigerated storage.

Broader nucleotide therapies can cause off-target effects; selective CTPS1 compounds target immune-related disorders with greater specificity.

A water-based blend of high- and low-molecular-weight PEG creates osmotic gradients that limit cell swelling and support capillary oxygen delivery.

Existing HS treatments have limited efficacy, high recurrence, and significant side effects; orismilast targets PDE4 to reduce inflammation and progression.

Topical collagen-matrix stromal stem cells support wound healing, while weight-based intravenous dosing improves liver function and reduces transplant needs.

This case uses a phenoxyacetic acid derivative to selectively activate PPARα, promote FGF21, and reduce visceral fat.

These covalent imidazopyrimidinone compounds inhibit WRN helicase and ATPase activity for MSI-H/dMMR cancers facing checkpoint resistance.

Enzyme-sensitive linkers help silica nanoparticle conjugates release drugs at tumors while targeting ligands limit off-target toxicity.

Antisense sequences bind and degrade LPA mRNA, while ASGPR-mediated uptake targets hepatocytes to lower Lp(a) levels.

Poor water solubility can limit camptothecin ADC loading and increase aggregation and toxicity; modified derivatives support higher DAR values.

A carbamate-linked photocleavable group blocks translation until light removes it and restores the native mRNA cap.

A retrieval flange lets forceps extract the biodiffusion chamber without grasping its fragile membrane-enclosed body, reducing puncture and leakage risk.

Existing HbF-inducing therapies can cause genotoxicity, neutropenia, or variable responses; these compounds target WIZ to induce HbF.

Freeze-drying rilpivirine with hyaluronidase preserves enzyme stability and particle size for storage and prolonged-release HIV treatment.

Organic acids and tuned surfactants help a Minoxidil foam inhibit crystals, preserve solubility, and improve topical feel while limiting irritation.

This crystalline PI3Kα inhibitor targets mutant enzyme pockets while sparing wild-type activity, potentially reducing hyperglycemia and hyperinsulinemia.

Drug-resistant TNBC is addressed with tinostamustine alone or alongside olaparib, including BRCA-1 wildtype and BL1 subtypes.

Alternative salt forms address Compound 1’s limited bioavailability and short half-life for GABAA receptor modulation.

A reversed 1:10 inhibitor-to-amyloid beta ratio suppresses aggregation at low dose while improving detoxifying effects.

Ionizable polymers complex with mRNA to improve targeted delivery while reducing off-target effects and immunogenicity.

Affinity-tuned anti-c-MET CARs kill high-expression tumor cells while limiting healthy-tissue toxicity and supporting T-cell persistence.

Arylborono groups reversibly bind membrane-bound mucins to keep lubricants and drugs on the eye longer without frequent application.

Heterocyclic compounds allosterically inhibit cardiac myosin to improve sarcomere selectivity while limiting cell damage and arrhythmogenic effects.

This mRNA structure uses liver-specific miR-122 to reduce hepatocyte expression while retaining stability and translation elsewhere.

An 8–32 mg/day initial phase followed by reduced maintenance dosing sustains treatment effects for JAK-related disorders.

This case uses body-surface-area dosing and response-based adjustments to reduce inoperable pediatric NF1-PN volume and pain.

Dexpramipexole lowers eosinophil and basophil levels without corticosteroid drawbacks.

This case uses low-temperature roller compaction to improve CoQ10 density and flowability without thermal decomposition or excipients.

This case uses protonated H-type ulvan to combine mitochondria activation, collagen biosynthesis, and antioxidant action in one agent.

This case uses selective GCN2 inhibitors to interrupt amino acid depletion signaling and restore anti-cancer immune activity.

This formulation combines defined hyaluronic acid with lemon and neem extracts to restore mucosal integrity and limit relapse.

Etifoxine blocks β-amyloid action to limit neuronal damage beyond symptom relief.

Pediatric oral CRF1 formulations improve bioavailability for CAH treatment.

This case uses pyrimidine-based macrocycles to selectively inhibit CDK9 and address poor efficacy and adverse events.

Chemically modified RNA pairs with LPA mRNA, while ASGPR targeting delivers it to hepatocytes with reduced inflammatory risk.

This case uses asymmetric siRNA to silence androgen receptor mRNA, supporting hair growth with fewer off-target and systemic effects.

This case develops an annulated pyridazine derivative to inhibit NLRP3 activation in inflammatory and neurodegenerative diseases.

This case uses sequence-optimized guide RNA to target VEGFA and balance editing efficiency, specificity, and safety.

The case develops variable-substituent bipyrazole compounds to inhibit JAK activity across applications including cancer.

This case uses substituted pyrazolopyridines to improve FGFR3 potency and selectivity while reducing dose-limiting FGFR1 toxicity.

This case validates anti-IL-6 receptor antibodies in EAU mice despite incomplete understanding of IL-6 mechanisms.

SDP and FOS combine in animal food to support gut health and reduce malodour.

Selective 7-azaindole compounds inhibit AXL kinase and block viral entry.

Targeted UNC13A ASOs prevent aberrant splicing caused by TDP-43 depletion, restoring functional protein expression.

Oxetane-substituted chitosan polyurethane networks enable self-repair through cyclic oxide ring opening triggered by ultraviolet light exposure.

Pyrazine derivatives enable real-time renal function assessment by replacing delayed urine collection with optical detection of luminescent compounds.

Exogenous G-CSF or GM-CSF induces neutrophilia to constrain cancer progression in colon and pancreatic models.

Dry powder formulation delivers local anesthetics to conductive airways via controlled particle size, reducing systemic toxicity risks.

A Centipeda minima extract composition containing Brevilin A and Arnicolide D inhibits JAK-STAT signaling pathways.

Injectable combination of calcium hydroxyapatite and polidocanol addresses both connective tissue structure and local fat volume simultaneously.

Novel GLP-1 receptor agonist compounds enable oral administration while minimizing cardiotoxicity risks associated with existing injectable treatments.

Modifying withaferin A structures prevents disease progression and reverses neuronal damage, addressing limitations of current symptomatic therapies.

Anhydrous saxagliptin hydrochloride crystal forms eliminate high water content that causes chemical instability and processing clogging.

Combining N-cadherin with FGFR1 and FGFR4 expression levels enables precise patient stratification for targeted lung cancer therapy.

Selective ITK and JAK3 inhibitors block IL-2 and IL-4 signaling to treat autoimmune diseases without broad-spectrum hematopoiesis disruption.

Selective USP7 inhibitors degrade HDM2 to restore p53 function, reducing toxicity from broad proteasome blockade.

Adjusting pH between 6.0 and 8.0 prevents precipitation when mixing insulin glargine with insulin aspart, reducing injection frequency.

Modified coumermycin A1 analogs with piperidine substitutions overcome high IC50 values of parent compounds by enhancing HSP90 binding affinity.

Segmented compartments and moisture barrier prevent humidity-induced chemical degradation, extending shelf life of dialysis acid precursor compositions.

Removing genotoxic dibenzyl impurities from safinamide synthesis via intermediate purification to ensure clinical safety.

Sulfonamide derivatives with terminal phenyl or heterocyclic groups inhibit alpha4 integrins.

A butyrylated cellulose derivative releases butyric acid to increase intestinal Th1 cells.

C5-anilinoquinazoline compounds inhibit KIT kinase activity with high selectivity against KDR receptors.

Lysine salts of phenoxyalkyl thio-phenoxyacetic acid derivatives act as potent PPAR delta agonists.

Weekly cobitolimod dosing of 100 to 350 mg overcomes side effects and loss of response from glucocorticosteroids.

Lysophospholipids activate the PKA signaling pathway to upregulate lipolysis, reducing body weight and fat mass in metabolic disease treatment.

Optimized alcohol content prevents crystallization and degradation in aqueous Methisoprinol formulations for safe parenteral administration.

Compounds with specific stereochemistry inhibit O-GlcNAcase while excluding lysosomal beta-hexosaminidases.

A lipophilic small molecule compound penetrates the blood-brain barrier to deliver therapeutically significant concentrations for treating brain cancers.

Dihydropyrimidinoisoquinolinone compounds antagonize GPR84 receptors, resolving the lack of specific targeting in current inflammatory therapies.

A chewable fixed combination of hyaluronic acid, chondroitin sulfate, and aluminum hydroxide adheres to the gastric mucosa.

Hydrolysed starch and guar gum create a stable, water-soluble fiber that modifies the gastrointestinal environment to slow nutrient absorption.

Azabicyclo octane derivatives inhibit dipeptidyl peptidase IV to preserve glucagon-like peptide-1 bioactivity.

Alkoxy-substituted imidazoquinolines inhibit DNA-PK to enhance cancer cell radiosensitivity while minimizing off-target PIKK family toxicity.

Novel compounds bind the colchicine site on tubulin to inhibit polymerization and arrest cell cycles in cancer cells.

Targeted DNA carriers resolve specificity trade-offs by using pH-responsive release mechanisms inside acidic endosomes.

Optimizing topical estradiol doses to 0.375 mg/day resolves the trade-off between therapeutic effectiveness and patient safety.

Allosteric modulators bind the ribonucleotide reductase hexamer interface, avoiding nonspecific binding side effects from nucleoside-based chemotherapies.

Albumin nanoparticles encapsulate arsenic trioxide via solvent removal, resolving toxicity and stability issues in cancer treatment.

Administering idronoxil at biomarker-defined thresholds prevents sepsis progression by reducing cytokine levels and organ damage severity.

Stable cyclopentane hydrate compound enables parenteral neuraminidase inhibitor therapy, addressing oral drug limitations in high-risk patients.

Dry powder epinephrine bypasses invasive injections to treat anaphylaxis via rapid nasal mucosa absorption.

Monovalent alginate reacts with gastric acid to form a protective gel that preserves enzyme activity until intestinal release, lowering formulation costs.

A topical gel composition uses a non-carbomer rheology modifier to achieve controlled viscosity for effective active agent delivery.

Solid composition with fermented red rice extract and CoQ10 forms an extemporaneous emulsion to enhance enteric bioaccessibility.

Enzyme-cleaved phosphate surfactant micelles release drugs at prostate cancer sites, reducing systemic toxicity.

Segmented monoglutamate prodrugs convert via FPGS enzymes inside cancer cells, reducing toxicity to normal tissues.

Ethyl acetate crystallization reduces residual solvent content below ICH limits while maintaining rocuronium bromide purity above 98 percent.

A steroid compound inhibits the SREBP pathway to reduce hepatic lipid accumulation.